These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25093849)

  • 1. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
    Li Q; Yan H; Liu W; Zhen H; Yang Y; Cao B
    PLoS One; 2014; 9(8):e104346. PubMed ID: 25093849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer.
    Li Q; Yuan Z; Yan H; Wen Z; Zhang R; Cao B
    Clin Ther; 2014 Jul; 36(7):1054-63. PubMed ID: 24986485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
    Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
    J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
    Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
    Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
    Heinemann V; Boeck S; Hinke A; Labianca R; Louvet C
    BMC Cancer; 2008 Mar; 8():82. PubMed ID: 18373843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone.
    Xie de R; Liang HL; Wang Y; Guo SS
    Chin J Dig Dis; 2006; 7(1):49-54. PubMed ID: 16412038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis.
    Ouyang G; Liu Z; Huang S; Li Q; Xiong L; Miao X; Wen Y
    World J Surg Oncol; 2016 Feb; 14():59. PubMed ID: 26927942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
    Herrmann R; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi B; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Cina S; Bernhard J; Dietrich D; Scheithauer W; ;
    J Clin Oncol; 2007 Jun; 25(16):2212-7. PubMed ID: 17538165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
    Ciliberto D; Botta C; Correale P; Rossi M; Caraglia M; Tassone P; Tagliaferri P
    Eur J Cancer; 2013 Feb; 49(3):593-603. PubMed ID: 22989511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
    Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
    Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
    Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
    J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
    Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
    Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
    Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
    BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
    Barone C; Cassano A; Corsi DC; Pozzo C; Longo R; Schinzari G; Quirino M; Battelli C; Basso M
    Oncology; 2003; 64(2):139-45. PubMed ID: 12566911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.